Significant Revenue Growth
Total revenue for Q3 2025 was $27.6 million, up from $16 million in Q3 2024, primarily due to a $25 million milestone from J&J related to pasritamig's clinical progress.
Promising Clinical Data for ZW191
ZW191 showed encouraging Phase I data with a high objective response rate of 64% in certain doses and a favorable safety profile, supporting its potential as a best-in-class folate receptor alpha directed ADC.
Strong Financial Position
Despite a net loss of $19.6 million, the company maintains $299.4 million in cash and anticipates funding operations until the second half of 2027.
Progress in Partnered Programs
Milestone revenue recognition from partnerships and strong performance in partnered programs, such as the collaboration with J&J and trials with Jazz, highlight the strength of Zymeworks' collaborations.